Anti-FOLR1 Immunoconjugate Dosing Regimens

摘要

Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.

主权项

1. A method for treating a human patient having an FOLR1-expressing ovarian cancer comprising administering to the patient an amount of an immunoconjugate that binds to FOLR1 polypeptide, wherein the amount
(a) is effective to produce area-under-the-curve (AUC)0-∞ of at least 12,500 hr·μg/mL and an AUG0-∞ of less than 20,000 hr·μg/mL, (b) is effective to produce an AUC0-∞ of at least 12,500 hr·μg/mL and an AUC0-24 of less than 3,000 hr·μg/mL, (c) is effective to produce an AUC0-∞ of at least 12,500 hr·μg/mL and is no more than 6 mg/kg, or (d) is effective to produce an AUC0-24 of at least 2,000 hr·μg/mL and less than 3,000 hr·μg/mL, and wherein the immunoconjugate comprises an antibody or antigen-binding fragment thereof that comprises the CDRs of SEQ ID NOs: 6-9, 11, and 12.